Susquehanna Initiates Coverage on SciClone Pharmaceuticals (SCLN) with a Neutral
More News related to SCLN
- SciClone Pharmaceuticals (SCLN) to Receive $6M in Debt Financing from Silicon Valley Bank
- SciClone (SCLN) and FDA Reach Agreement to Design Phase 3 Trial for Thymalfasin
- SciClone Reaches Agreement With FDA on Special Protocol Assessment for Phase 3 Thymalfasin Trial in Stage IV Melanoma
- Susquehanna Maintains a Positive Rating on SciClone Pharmaceuticals (SCLN)
- SciClone Reports 52% Revenue Growth and a Profit in the Third Quarter of 2008
More News related to New Coverage
- Friedman Billings Starts Aircastle (AYR) at Underperform
- Friedman Billings Starts Netflix (NFLX) at Market Perform
- Credit Suisse Starts 3PAR (PAR) at Neutral
- Credit Suisse Starts Netezza (NZ) at Neutral
- FBR Starts Amazon.com (AMZN) at Market Perform
Susquehanna initiates coverage on SciClone Pharmaceuticals (Nasdaq: SCLN) with a Neutral.
Susquehanna analyst says, "Our rating is driven by our concerns for the outcome of the Sigma Tau EU trial for Zadaxin. We do believe that the existing value of SPIL (SciClone Pharmaceutical International China Limited), where Zadaxin is expected to reach $50 mln in top-line revenue this year, does justify a higher valuation; however, we believe investors are ignoring the value in SPIL in front of the Zadaxin outcome expected soon. Based on our analysis of the data, we believe that if statistical significance is reached, it will be only minimally so, and as such, we are not very enthusiastic for the outcome."
SciClone Pharmaceuticals, Inc. (SciClone ) is a biopharmaceutical company engaged in the development and commercialization of therapeutics to treat life-threatening diseases.
Related Categories
New CoverageStocks Mentioned
+0.03Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
